Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital Tuebingen
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
Age ≥ 65 years
Mild to moderate symptomatic respiratory tract Infection defined as not requiring hospital admission: SpO2 \>94%, respiratory rate \<20, mental state alert, no signs of septic shock
Proven SARS-Cov2 infection by throat swab (PCR)
Onset of symptoms within the last 3 days before randomization
Must be able to adhere to the study visit schedule and other protocol requirements in the investigator's opinion. I.e. must be able to answer to questions concerning symptoms and side effects and must be able to consent to the informed consent.
You may not be if
Hospitalization at study inclusion
Weight \<50 kg
Acute myocardial infarction
Severe heart failure, characterized as NYHA class 3 or 4
Use of concomitant medications that prolong the QT/QTc interval.
QTc \>450ms
Bilirubin ≥ 1,5 x UNL, (except for known M. Meulengracht)
AST/ALT ≥ 3 x ULN
Albumine ≤ 2.8 g/dl
Hemoglobin ≤ 9 g/dl
Leucocytes ≤ 2000/µl
Neutrophiles ≤ 1000/µl
Thrombocytes ≤ 100.000/µl
Troponin elevation
BNP \> 500 pg/ml
Creatine kinase \> 5 x ULN
Creatinine \>1,5 mg/dl
Uncorrected hypopotassemia or hypomagnesemia
History of hypoglycemic events
History of or present cardial arrhythmia (except atrial fibrillation or paroxysmal supraventricular tachycardia)
Bradycardia \< 60 beats/min
History of Retinopathy or Maculopathy
Psoriasis
Myasthenia gravis
Epilepsy
Immunodeficiency syndromes or need for highly immunosuppressive medication
Pre-existing medication with hydroxychloroquine
Known G6PD deficiency.
Participation in another interventional study
Known hypersensibility to hydroxychloroquine and its derivates
